Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $34.57.

Several equities research analysts recently weighed in on DAWN shares. HC Wainwright cut their target price on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Wedbush restated an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Bank of America reduced their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. cut their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN traded up $0.59 during mid-day trading on Friday, reaching $8.66. 1,685,642 shares of the company were exchanged, compared to its average volume of 1,224,732. Day One Biopharmaceuticals has a 1 year low of $7.88 and a 1 year high of $18.07. The firm's 50-day simple moving average is $11.68 and its 200 day simple moving average is $13.15. The firm has a market cap of $877.73 million, a price-to-earnings ratio of -8.41 and a beta of -1.38.

Remove Ads

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. On average, research analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now directly owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares of the company's stock, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,064 shares of company stock valued at $251,925. Corporate insiders own 8.40% of the company's stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Day One Biopharmaceuticals during the fourth quarter worth $27,000. R Squared Ltd acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $31,000. Quest Partners LLC boosted its position in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after buying an additional 7,668 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Day One Biopharmaceuticals by 911.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock valued at $135,000 after acquiring an additional 9,603 shares during the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $143,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.